Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis.

Autor: Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, Schadendorf D, Büttner P, Garbe C, Pawelec G

Publikováno v: Journal of Clinical Oncology; 5/20/2012, Vol. 30 Issue 15, p1835-1841, 7p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies.

Autor: Scott JI; Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK., Mendive-Tapia L; Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK., Gordon D; Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK., Barth ND; Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK., Thompson EJ; Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK., Cheng Z; Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK., Taggart D; Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK., Kitamura T; MRC Centre for Reproductive Health, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK., Bravo-Blas A; Cancer Research UK Beatson Institute, Glasgow, UK., Roberts EW; Cancer Research UK Beatson Institute, Glasgow, UK., Juarez-Jimenez J; EaStChem School of Chemistry, Joseph Black Building, The University of Edinburgh, Edinburgh, UK., Michel J; EaStChem School of Chemistry, Joseph Black Building, The University of Edinburgh, Edinburgh, UK., Piet B; Department of Pulmonary Diseases, Radboud University Medical Centre, Nijmegen, Netherlands., de Vries IJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, Netherlands., Verdoes M; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, Netherlands., Dawson J; Cancer Research UK Edinburgh Centre, The University of Edinburgh, Edinburgh, UK., Carragher NO; Cancer Research UK Edinburgh Centre, The University of Edinburgh, Edinburgh, UK., Connor RAO; Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK., Akram AR; Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK., Frame M; Cancer Research UK Edinburgh Centre, The University of Edinburgh, Edinburgh, UK., Serrels A; Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK., Vendrell M; Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK. marc.vendrell@ed.ac.uk.

Publikováno v: Nature communications [Nat Commun] 2022 May 02; Vol. 13 (1), pp. 2366. Date of Electronic Publication: 2022 May 02.

Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma.

Autor: Vasaturo A; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands., Di Blasio S; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands., Verweij D; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.; Department of Pathology, Radboud University Medical Centre, Nijmegen, the Netherlands., Blokx WA; Department of Pathology, Radboud University Medical Centre, Nijmegen, the Netherlands., van Krieken JH; Department of Pathology, Radboud University Medical Centre, Nijmegen, the Netherlands., de Vries IJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Figdor CG; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.

Publikováno v: Histopathology [Histopathology] 2017 Mar; Vol. 70 (4), pp. 643-649. Date of Electronic Publication: 2016 Dec 02.

Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.

Autor: Bol KF; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., van den Bosch T; Department of Ocular Oncology, Rotterdam Eye Hospital, Rotterdam, The Netherlands., Schreibelt G; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands., Mensink HW; Department of Ocular Oncology, Rotterdam Eye Hospital, Rotterdam, The Netherlands; Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands., Keunen JE; Department of Ophthalmology, Radboud University Medical Centre, Nijmegen, The Netherlands., Kiliç E; Department of Ophthalmology, Erasmus Medical Centre, Rotterdam, The Netherlands., Japing WJ; Department of Ophthalmology, University Medical Center Groningen, Groningen, The Netherlands., Geul KW; Department of Internal Medicine, Sint Franciscus Hospital, Rotterdam, The Netherlands., Westdorp H; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Boudewijns S; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Croockewit SA; Department of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands., van Rossum MM; Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands., de Goede AL; Department of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands., Naus NC; Department of Ophthalmology, Erasmus Medical Centre, Rotterdam, The Netherlands., van der Graaf WT; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Medical Oncology, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, United Kingdom., Gerritsen WR; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., de Klein A; Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands., Punt CJ; Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands., Figdor CG; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands., Cohen VM; Department of Ophthalmology, Moorfields Eye Hospital and St. Bartholomew's Hospital, London, United Kingdom., Paridaens D; Department of Ocular Oncology, Rotterdam Eye Hospital, Rotterdam, The Netherlands; Department of Ophthalmology, Erasmus Medical Centre, Rotterdam, The Netherlands., de Vries IJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands. Electronic address: Jolanda.deVries@radboudumc.nl.

Publikováno v: Ophthalmology [Ophthalmology] 2016 Oct; Vol. 123 (10), pp. 2265-7. Date of Electronic Publication: 2016 Jul 29.